174
Participants
Start Date
July 13, 2020
Primary Completion Date
October 24, 2024
Study Completion Date
July 1, 2027
Paclitaxel
Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
Pertuzumab
Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Margetuximab
Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Trastuzumab
Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
Montefiore Medical Center, The Bronx
University of Pittsburgh Medical Center, Pittsburgh
UPMC Hillman Cancer Center - Arnold Palmer at Mountain View, Greensburg
UPMC Hillman Cancer Center - Arnold Palmer at Norwin, Irwin
Georgetown University Medical Center, Washington D.C.
MedStar Washington Hospital Center, Washington D.C.
Baylor College of Medicine Medical Center, Houston
MD Anderson Cancer Center, Houston
University of Washington Fred Hutchinson Cancer Care, Seattle
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
Dana-Farber at Milford, Milford
Dana-Farber at South Shore Hospital, Weymouth
Collaborators (1)
MacroGenics
INDUSTRY
Translational Breast Cancer Research Consortium
OTHER
Dana-Farber Cancer Institute
OTHER